ASSOCIATION BETWEEN TREATMENT
ADHERENCE AND DEPRESSION IN PATIENTS
WITH HIV/AIDS
ASOCIACIÓN ENTRE ADHERENCIA AL TRATAMIENTO Y
DEPRESIÓN EN PACIENTES CON VIH/SIDA
Dr. Marcos Ivan Tienda-Pimentel PhD
Institute of Sciences and Higher Studies Tamaulipas, México
Dra. Eréndira Rodríguez Román
High-Specialty Regional Hospital ISSSTE Veracruz, México
Dra. Ingrid Jiménez Morales
Independent Researcher, México
Dra. Ana Sofia Torres Dibildox
Independent Researcher, México
pág. 3579
DOI: https://doi.org/10.37811/cl_rcm.v8i4.12591
Association between Treatment Adherence and Depression in Patients with
HIV/AIDS
Dr. Marcos Ivan Tienda-Pimentel PhD1
marcos.711@hotmail.com
https://orcid.org/0000-0003-0580-6807
Private Practice
Institute of Sciences and Higher Studies
Tamaulipas, A.C.
Mexico
Dra. Eréndira Rodríguez Román
roman.mls@outlook.com
https://orcid.org/0009-0005-2473-7028
Private Practice
Epidemiology Department
High-Specialty Regional Hospital ISSSTE Veracruz
Mexico
Dra. Ingrid Jiménez Morales
ingridjimenez.mls@gmail.com
https://orcid.org/0009-0005-3649-5089
Private Practice
Independent Researcher
Mexico
Dra. Ana Sofia Torres Dibildox
sofiadbx@gmail.com
https://orcid.org/0009-0004-0057-188X
Private Practice
Independent Researcher
Mexico
ABSTRACT
Background: Depression represents a significant issue among individuals diagnosed with HIV. A study
conducted in Africa revealed that the prevalence of depression in this patient population may reach
63.1%. In Mexico, however, there is no existing literature on this matter. Antiretroviral therapy (ARV)
is a vital component of treatment for individuals with HIV/AIDS. However, the efficacy of ARV may
be compromised by poor adherence to treatment. The lack of adherence may be attributed to
psychological factors, such as depression. Objective: To determine the presence and severity of
depression and its relationship with adherence to treatment in patients with HIV/AIDS. Methods: A
quantitative, non-experimental, cross-sectional, and non-interventional study was conducted at the
High-Specialty Regional Hospital ISSSTE (Institute for Social Security and Services for State Workers)
in Veracruz, Mexico. Unit of analysis: 977 individuals, selected according to the pre-established
inclusion and exclusion criteria, with a confidence level of 99% and a confidence limit of 3.8%.
Discussion: The lack of adherence to treatment in patients with HIV/AIDS was found to be directly
proportional to the presence and severity of depression. Depression was identified in 81.17% of the total
sample. 62.79% exhibited mild depression, 16.27% demonstrated moderate depression, and 20.93%
displayed severe depression. In patients with poor adherence to treatment, severe depression was found
in 91.37%. Additionally, comorbidities such as diabetes and hypertension were observed with a higher
frequency than reported in literature. Conclusion: We recommend establishing a systematic and
individual psychological evaluation of HIV/AIDS patients and initiating measures for the early
detection of depression. This approach will help to prevent a possible interruption or abandonment of
antiretroviral treatment, and therefore therapeutic failure.
Keywords: HIV, treatment, adherence, antiretroviral, depression, comorbidities
1
Autor principal
Correspondencia: marcos.711@hotmail.com
pág. 3580
Asociación entre Adherencia Al Tratamiento y Depresión en Pacientes con
VIH/SIDA
RESUMEN
Antecedentes: La depresión es un factor clave entre individuos con VIH. Un estudio realizado en África
mostró que la prevalencia de depresión en estos pacientes puede ser de hasta 63,1%. En México, sin
embargo, no existe referencia respecto a este tema. El tratamiento antirretroviral (TAR) es indispensable
en pacientes con infección por VIH/SIDA, y su fracaso puede deberse a la falta de adherencia a éste.
La pobre adherencia puede deberse a variables psicológicas como la depresión. Objetivo: Determinar
la presencia de depresión, así como el grado de la misma y su relación con la adherencia al tratamiento
en pacientes con VIH/SIDA. Material y Métodos: Se realizó un estudio cuantitativo, no experimental,
transversal y no intervencionista en pacientes adultos con VIH/SIDA con y sin tratamiento
antirretroviral del Hospital Regional De Alta Especialidad ISSSTE Veracruz, en la ciudad de Veracruz,
México. Unidad De Análisis: 977 personas, siguiendo los criterios de inclusión y exclusión, con un
nivel de confianza de 99% y un limite de confianza de 3.8%. Discusión: La falta de adherencia al
tratamiento en pacientes con VIH/SIDA fue directamente proporcional a la presencia de depresión y a
la severidad de la misma. La depresión se encontró en el 81.17% de la muestra total. De estos, el 62.79%
tenía depresión leve, 16.27% depresión moderada y 20.93% depresión severa. En pacientes con poca
adherencia al tratamiento, la depresión severa se encontró en el 91.37%. Además, comorbilidades como
diabetes e hipertensión arterial se encontraron con una frecuencia mayor a la reportada en la
bibliografía. Conclusión: Recomendamos establecer de manera sistemática e individual la evaluación
psicológica de los pacientes con VIH/SIDA e iniciar medidas para la detección temprana de depresión,
con el fin de prevenir una posible interrupción o abandono del tratamiento antirretroviral y por ende el
fracaso terapéutico.
Palabras clave: VIH, tratamiento, adherencia, antirretrovirales, depresión, diabetes, hipertensión,
comorbilidades
Artículo recibido 03 julio 2024
Aceptado para publicación: 05 agosto 2024
pág. 3581
INTRODUCTION
The human immunodeficiency virus (HIV), first isolated in 1983, is a retrovirus that causes the
destruction of the immune system through its tropism for macrophages and for CD4+ T lymphocytes.
There are two types of HIV: HIV-1 and HIV-2.1
The virus is transmitted through the body fluids of infected individuals, including blood, breast milk,
semen, and vaginal secretions. Additionally, it can be transmitted to the fetus during pregnancy and
childbirth. It is not transmitted by contact such as kissing, hugging, or handshaking, nor by sharing
personal items, water, or food.2 Antiretroviral drugs are the primary treatment for HIV infection, and
their effectiveness depends largely on adherence to treatment.
The World Health Organization (WHO) defines adherence to treatment as the act of taking the
prescribed medication in accordance with the recommended dosage and schedule and maintaining this
regimen over time.3 This encompasses not only taking the medication as directed, but also aligning
one's lifestyle habits with the advice of a healthcare professional.4
Antiretroviral treatment (ARV) is a vital component of the management of HIV/AIDS infection. The
efficacy of ARV in suppressing the viral load depends on the patient's strict adherence to the treatment
regimen, which requires a high level of commitment. Previous research has demonstrated that good
adherence to ARV is associated with a reduced likelihood of depressive behaviors and the absence of
addictions. However, this was not found to be associated with quality-of-life improvement.5
HIV infection continues to represent a significant global public health concern. According to the WHO,
approximately 1.3 million individuals acquired HIV in 2022, resulting in an estimated 39 million people
living with the disease by the end of that year. Additionally, an estimated 360,000 deaths were attributed
to HIV-related causes.2
In 1981, several cases of pneumonia and Kaposi's sarcoma were diagnosed simultaneously in the United
States. The following year, these diagnoses were defined as AIDS and were predominantly among
homosexual men, which led to the erroneous assumption that AIDS was a disease exclusive to
homosexuals. However, over time, new cases were reported in other groups and individuals who had
engaged in sexual intercourse with HIV-positive individuals.6
pág. 3582
In 1983, the first case of HIV/AIDS was reported in Mexico.7 From that point until April 15th, 2024, a
total of 375,296 confirmed cases have been registered nationwide. Of these cases, 82%, or 307,770
cases, were identified in men, while 18%, or 67,526 cases, were identified in women. In the course of
2023, 17,739 new cases were documented nationwide, with an incidence rate of 13.5 per 100,000
inhabitants. 8
An epidemic caused by the Human Immunodeficiency Virus (HIV) has been reported in the Mexican
state of Veracruz. According to the latest report issued by the Ministry of Health, a total of 34,628 cases
have been reported from 1983 to the first quarter of 2024, representing 9.2% of the total cases reported
in the country. 8
1,584 new HIV cases were reported in Veracruz during 2023, representing an incidence of 18.3 per
100,000 inhabitants.8 As indicated in the Bulletin of Comprehensive Care for People Living with HIV
of the National Center for the Prevention and Control of HIV and AIDS in Mexico (CENSIDA), by the
end of the same year, the state of Veracruz had 11,262 individuals undergoing antiretroviral treatment.9
Mexico has adopted a progressive approach to the HIV epidemic from its earliest stages. Since 2003,
the country has provided free antiretroviral therapy to all people living with HIV through a network of
outpatient centers. These include Centers for the Prevention and Care of HIV/AIDS and Sexually
Transmitted Infections (CAPASITS), the network of Comprehensive Care Services (SAIH) clinics for
the uninsured, and social security clinics.10 Nevertheless, 4,828 individuals died from HIV-related
causes across the country in 2022. 8
The occurrence of ARV failure in patients with HIV may be attributed to non-adherence11, which in turn
may be associated with poor quality of life and/or psychological factors such as depression.
Depression represents a significant public health concern in numerous countries, affecting millions of
individuals globally. It is estimated that millions of people worldwide suffer from depression. The
treatment of depressed patients typically involves the use of antidepressant drugs, psychological
therapy, or a combination of both. 12
Studies conducted in Mexico have documented the prevalence of mental disorders suffered by the
population. The National Survey of Psychiatric Epidemiology (ENEP) revealed that between 2001 and
pág. 3583
2022, 9.2% of the population had a depressive disorder in their lifetime, while 4.8% had experienced
such a disorder in the twelve months prior to the study. 13
Common comorbidities in patients with HIV include pneumonia, tuberculosis, toxoplasmosis, and
Kaposi's sarcoma, which are collectively referred to as opportunistic diseases. Other important
comorbidities are hypertension and diabetes, which can significantly impact the health status of
patients.14
In their 2020 documentary research, Morey Gabriel and Zambrano Rosario identified several
opportunistic infections prevalent in Latin America, including cerebral toxoplasmosis, mucocutaneous
candidiasis, pulmonary tuberculosis, Pneumocystis jirovecii pneumonia, and invasive candidiasis. The
2019 Annual Bulletin of the Ministry of Public Health of Ecuador identified tuberculosis as the most
frequent opportunistic infection.14
In addition to the physical comorbidities associated with HIV, individuals who are HIV-positive also
experience psychological disturbances and a higher incidence of depression and anxiety than
individuals who are HIV-negative. 15
Depression is a significant concern among individuals with HIV. Therefore, it is essential to assess the
psychological status of patients.16 A study by Abdulateef Elbadawi and colleagues showed that the
prevalence of depression among patients with HIV/AIDS can reach as high as 63.1%. 17
Depression is a risk factor for HIV infection and impairs adherence to medical treatment and safe sex
practices that prevent further transmission of the virus. There is evidence that supports the efficacy of a
combined psychotherapy and pharmacotherapy approach for the treatment of depressive symptoms.18
Waldron et al, 2021 mention that the symptomatology of depression and anxiety increases to a greater
extent the physical and mental health problems of patients living with HIV; which decreases the level
of quality of life and prevents them from continuing with treatments, potentially due to a lack of
comprehension of the meaning of life and a diminished motivation to improve. 19
The diagnosis of depression is a clinical process in which the results of structured interviews can also
be used. Several self-rating scales are available, such as Zung's Self-Rating Depression Scale (SDS), an
established norm-based screening measure to identify the presence of depressive disorders in adults; it
pág. 3584
is used worldwide in clinical and research assessments of depressive symptoms and severity of
depression.20,21,22
Zung developed a method for scoring both depression and anxiety that involved conversion of a total
scale raw score (with a potentail range of 20 to 80) to a index score with a potential range of 25 to 100.
The index score is derived by dividing the sum of the values (raw scores) obtained on the 20 items by
the maximum possible score of 80, converted to a decimal and multiplied by 100. 23 It is important to
mention the scoring criteria established in the scale: (<50 without depression, 50-59 with mild
depression, 60-69 moderate depression and ≥ 70 severe depression). 24
METHODS
A quantitative, non-experimental, cross-sectional, and non-interventional study was conducted in adult
patients of both sexes confirmed positive for HIV/AIDS with and without antiretroviral treatment, who
are patients of the High-Specialty Regional Hospital ISSSTE (Institute for Social Security and Services
for State Workers) in Veracruz, Veracruz, Mexico and are assigned to different departments of this
hospital.
Unity of Analysis
The subjects of this study were 977 individuals who met the inclusion and exclusion criteria mentioned
below. The Zung Self-Rating Depression Scale was used to assess the presence and severity of
depression in these subjects. This scale has been validated in different countries and languages and is
available in a simplified version with 20 items.
Based on the sample size provided by CENSIDA 2023 and the expected frequency of the phenomenon
of 63.1%, a confidence level of 99% and a confidence limit of 3.8% were obtained.
Additionally, a brief identification survey was conducted to gather information regarding the patient's
age, sex, and place of residence. This was also done to determine whether the patient was adhering to
antiretroviral treatment, the duration of which was also documented. Furthermore, the survey inquired
about whether the patient had ever voluntarily discontinued treatment, whether they had resumed
treatment after a period of discontinuation, or if they had completely abandoned treatment. This
instrument has been previously validated by experts in the field at the mentioned hospital.
pág. 3585
It is noteworthy that not all patients who were on the seropositive lists attended the epidemiology
department or the outpatient clinic. In addition, some patients declined to participate in the survey for
various reasons, including social stigma.
In accordance with the standards set forth by the institution's ethics committee, the surveys were applied
individually and anonymously in a setting that was both comfortable and private, with optimal lighting
and a pleasant room temperature.
Inclusion criteria
Patients between the ages of 18 and 65 years old, diagnosed with HIV/AIDS, who were admitted to
the internal medicine hospitalization area of the High-Specialty Regional Hospital ISSSTE Veracruz.
Patients between the ages of 18 and 65 years with a diagnosis of HIV/AIDS who were attending
follow-up visits to the epidemiology department of the High-Specialty Regional Hospital ISSSTE
Veracruz.
Patients between the ages of 18 and 65 years who had been diagnosed with HIV/AIDS and who
attended outpatient specialty consultations at the High-Specialty Regional Hospital ISSSTE
Veracruz.
Exclusion criteria
Individuals under the age of 18.
Individuals aged 65 years and above.
Patients who are unable to respond to the questionnaire due to psychomotor limitations.
Individuals who decline to participate.
RESULTS
All 977 patients surveyed met the inclusion criteria and are the subject of this study. The 126 patients
who did not agree to participate in the study and were therefore excluded provided various reasons for
their decision, including social stigma and concerns about feeling safe to be interviewed about their
disease due to potential reactions from individuals outside of the disease community. These patients
also reported experiencing discrimination on numerous occasions.
pág. 3586
Of the 126 patients excluded from the study, 47 (37.30%) reported engaging in unprotected sexual
intercourse with multiple partners without revealing their HIV-positive status. Among the 977 patients
included in the study, 267 (27.33%) had sexual intercourse with one or multiple partners without
informing them of their HIV-positive status, primarily due to concerns about rejection or a lack of
concern about potential HIV transmission.
The mean age of the 977 patients who participated in this study was 44 years (with an age range of 18-
65 years). Of the total sample, 329 were female (33.7%), while 66.3% of the sample were male, with
648 patients. [Graph 1]
Of the 977 patients, 793 met the criteria for depression, with 498 classified as mildly depressed, 129 as
moderately depressed, and 166 as severely depressed. In other words, 81.17% of the patients included
were depressed, with 62.79% exhibiting mild depression, 16.27% demonstrating moderate depression,
and 20.93% displaying severe depression [Graph 2]. Of the total number of depressed patients, 307
were male (38.71%) and 486 (61.28%) were female.
A total of 41.24% (327) of patients with depression resided in the municipality of Veracruz within the
city of Veracruz (Mexican state of Veracruz). Of the remaining patients, 298 (37.58%) resided in the
municipality of Boca del Río, and 168 (21.19%) resided in other municipalities within the same city.
The largest proportion of patients with depression resided in the municipality of Veracruz. However,
the majority of these patients exhibited only mild depression, representing 79.54% of the total.
Meanwhile, the Boca del Río municipality had the highest percentage of severely depressed patients,
accounting for 71% of the total.
Regarding antiretroviral treatment, 780 of the total number of patients surveyed (79.84%) were
currently taking ARV. Of these, 120 patients (15.38%) dropped out at some point and resumed treatment
within 2 months of stopping, while the rest showed adequate adherence from the start. In contrast, 197
(20.1%) of the total sample did not adhere to their prescribed antiretroviral treatment.
180 (91.37%) of the 197 patients with poor adherence to treatment were severely depressed, 11 (5.58%)
were mildly depressed, and 6 (3.04%) were moderately depressed. [Graph 3]
pág. 3587
Additionally, 723 patients (74%) were found to have another disease, including diabetes mellitus,
hypertension, and some lymphatic malignancies.
The most prevalent comorbidity was diabetes, present in 467 individuals, representing 43.07% of the
total number of patients included in the study. Of the 467 diabetic patients, 256 had at least one
additional comorbidity. Hypertension was identified in 136 patients, accounting for 13.09% of the total
number of patients included in the analysis. [Graph 4]
A total of 156 patients (15.96%) of the 977 included had or presented tuberculosis as an opportunistic
infection at some point during their antiretroviral treatment. Some of these patients discontinued the
treatment by medical indication or by their own decision, resuming it later or abandoning it completely.
Among the patients with HIV/AIDS and active or previous tuberculosis, the majority reported having
had severe depression at some point in their illness, with some experiencing improvement at the time
of the study.
DISCUSSION
A review of the literature reveals a notable absence of references concerning the relationship between
adherence to antiretroviral treatment and depressive disorder in HIV patients in Mexico. Given the
chronic nature of HIV infection and the potential for a long life expectancy with adequate antiretroviral
treatment, it is crucial to identify the factors that may influence adherence to treatment over time.
Rejection and discrimination, frequently driven by religious beliefs or a lack of awareness about the
disease, can have a significant impact on the emotional well-being of individuals with HIV/AIDS,
leading to the development of isolation behaviors, anxiety, or feelings of sadness that may contribute to
the prevalence of depression in these patients.
As previously stated, numerous studies conducted globally have demonstrated a notable prevalence of
depression among individuals with HIV/AIDS. This is linked to a lack of adherence to antiretroviral
treatment.
In response, the Mexican Government has implemented strategies to address the public health crisis of
HIV/AIDS, ensuring access to care and information for users across both public and private sectors.
pág. 3588
The National Center for the Prevention and Control of HIV and AIDS (CENSIDA) provides health
services in all Mexican states, offering funding and supplies such as antiretroviral treatment and free
diagnostic tests. Additionally, it implements educational programs for all levels of medical care.
Furthermore, the government publishes regular bulletins containing surveys, annual statistics, and
quarterly information regarding the epidemiological status of the disease. Despite the occurrence of the
global pandemic caused by the SARS-CoV-2 virus between 2020 and 2023, the Government's action
program for the primary prevention of this disease or its timely diagnosis and treatment continued
uninterrupted.
CONCLUSION
The prevalence of depression was found to be 81.17%, which was higher than expected in this study
(63.1%). Of these, 62.79% were mildly depressed, 16.27% were moderately depressed, and 20.93%
were severely depressed.
The predominance of HIV/AIDS was in the male sex, but the predominance of depression was in the
female sex, as of the total number of depressed patients, 486 (61.28%) were women.
The percentage of patients on ARV was acceptable, with 780 patients (79.84%) of the total sample on
regular treatment. However, 15.38% of them had temporarily stopped treatment at some point.
Of the 197 patients with poor adherence, 100% were depressed: 91.37% were severely depressed,
5.58% were mildly depressed, and 3.04% were moderately depressed.
Given the above, it is important to note that in this study, lack of adherence to antiretroviral treatment
in patients with HIV/AIDS was directly proportional to the presence and severity of depression.
Additionally, 267 patients admitted having unprotected sex with partners who are unaware of their
condition, which accounts for 27.33% of the total sample. It is considered necessary to raise awareness
and educate patients with HIV about risky sexual practices and transmission of the virus.
The mortality rate due to HIV/AIDS in Mexico has not decreased in recent years. Therefore, there is a
need to intensify early detection efforts, link those found to be infected with HIV to care services and
implement measures to strengthen adherence to treatment. In addition, it is necessary to systematically
and individually assess the psychological status of these patients and initiate measures for the early
detection of depression, in order to prevent possible interruption or discontinuation of antiretroviral
pág. 3589
treatment and thus treatment failure, since this is closely linked to the prognosis and course of the
disease.
REFERENCES
1. Alzate C, Tabares R, Dahiana M, Almanza H, Martínez H, Hernández Á, et al. Virus de
inmunodeficiencia humana: hallazgos útiles en el diagnóstico, prevención y tratamiento.
Enfermedades Infecciosas y Microbiología [Internet]. 2019;39(2). Available from:
https://www.medigraphic.com/pdfs/micro/ei-2019/ei192e.pdf
2. World Health Organization. HIV and AIDS [Internet]. World Health Organization. 2023 [Cited
2024 Jun 6]. Available from: https://www.who.int/news-room/fact-sheets/detail/hiv-aids
3. García Valle S. Factores de riesgo de no adherencia al tratamiento en pacientes mayores de un
núcleo rural. Rev OFIL·ILAPHAR [Internet]. 2020 [Cited 2024 May 17];30(2):115–20.
Available from:
https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1699-714X2020000200115
4. Ramírez López GA, Gómez Galicia DL, Zagal Jiménez TX, Toledano Jaimes CD, Díaz de León
Castañeda C. Salud digital para promover la adherencia al tratamiento antirretroviral en
pacientes con VIH/sida: metarevisión. Farm Hosp [Internet]. 2024; Available from:
http://dx.doi.org/10.1016/j.farma.2024.02.005
5. Gutiérrez-Gabriel I, Godoy-Guinto J, Lucas-Alvarado H, Pineda-Germán B, Vázquez-Cruz E,
Hernández-De laRosa M, et al. Calidad de vida y variables psicológicas que afectan la
adherencia al tratamiento anti-retroviral en pacientes mexicanos con infección por VIH/SIDA.
Rev Chilena Infectol [Internet]. 2019 [Cited 2024 May 17];36(3):331–9. Available from:
https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-
10182019000300331&lng=en&nrm=iso&tlng=en
6. Lombó Fragueiro C. Repercusiones del estigma en la calidad de vida de los adultos con
VIH/SIDA: Una revisión sistemática. MLSPR [Internet]. 2021 Jun [Cited 2024 Jun 25];4(1).
Available from: https://www.mlsjournals.com/Psychology-Research-Journal/article/view/606
7. Día mundial del SIDA [Internet]. México: Centro Nacional para la prevención y control del
VIH y el SIDA; 2023 Dec [Cited 2024 May 26] p. 8. Available from:
pág. 3590
https://www.gob.mx/cms/uploads/attachment/file/873833/BOLETIN_DAI_ESPECIAL_2023
_30112023_1.pdf
8. Informe Histórico de VIH 1er Trimestre de 2024 [Internet]. Sistema de Vigilancia
Epidemiológica de VIH 2024. México: Dirección de Vigilancia Epidemiológica de
Enfermedades Transmisibles. Secretaría de Salud.; 2024 May [Cited 2024 May 30] p. 7-17.
Available from: https://www.gob.mx/salud/documentos/sistema-de-vigilancia-epidemiologica-
de-vih-2024
9. Boletín de Atención Integral de las Personas que Viven con VIH [Internet]. Centro Nacional
para la Prevención y Control del VIH y el SIDA; 2024 Mar [Cited 2024 Jun 29] p. 11. Available
from: https://www.gob.mx/censida/documentos/boletin-de-atencion-integral-de-personas-con-
vih
10. Avila-Rios S, García-Morales C, Reyes-Terán G, González-Rodríguez A, Matías-Florentino M,
Mehta SR, et al. Phylodynamics of HIV in the Mexico City metropolitan region. J Virol
[Internet]. 2022 [Cited 2024 May 15];96(14). Available from:
http://dx.doi.org/10.1128/jvi.00708-22
11. Nega J, Taye S, Million Y, Rodrigo C, Eshetie S. Antiretroviral treatment failure and associated
factors among HIV patients on first-line antiretroviral treatment in Sekota, northeast Ethiopia.
AIDS Research and Therapy. 2020 Jul 10;17(1). doi: 10.1186/s12981-020-00294-z.
12. Chen Chen, Elisabeth Beaunoyer, Matthieu J. Guitton, Jing Wang. Physical Activity as a
Clinical Tool against Depression: Opportunities and Challenges. J. Integr. Neurosci. 2022,
21(5), 132. https://doi.org/10.31083/j.jin2105132
13. Cerecero-García D, Macías-González F, Arámburo-Muro T, Bautista-Arredondo S. Síntomas
depresivos y cobertura de diagnóstico y tratamiento de depresión en población mexicana. Salud
Publica Mex. 2020;62:840-850. https://doi.org/10.21149/11558
14. Tumbaco-Quirumbay JA, Durán-Pincay YE. VIH/Sida en Ecuador: Epidemiología,
comorbilidades, mutaciones y resistencia a antirretrovirales. DC [Internet]. 2 de julio de 2021
[Cited 2024 Jul 25];7(3):341-54. Available from:
https://dominiodelasciencias.com/ojs/index.php/es/article/view/1997
pág. 3591
15. Meza-Rodríguez M del P, Farfan-Labonne B, Avila-García M, Figueroa-Damian R, Plazola-
Camacho N, Pellón-Díaz G, et al. Psychological distress, anxiety, depression, stress level, and
coping style in HIV-pregnant women in Mexico. BMC Psychol [Internet]. 2023 [Cited 2024
May 17];11(1). Available from: http://dx.doi.org/10.1186/s40359-023-01416-8
16. Rezaei S, Ahmadi S, Rahmati J, Hosseinifard H, Dehnad A, Aryankhesal A, Shabaninejad H,
Ghasemyani S, Alihosseini S, Bragazzi NL, Raoofi S, Kiaee ZM, Ghashghaee A. Global
prevalence of depression in HIV/AIDS: a systematic review and meta-analysis. BMJ Support
Palliat Care. 2019; 9(4): 404-412. doi: 10.1136/bmjspcare-2019-001952.
17. Elbadawi A, Mirghani H. Depression among HIV/AIDS Sudanese patients: a cross-sectional
analytic study. Pan African Medical Journal. 2017 Jan 30;26(43). Available from:
https://doi.org/10.11604/pamj.2017.26.43.10919
18. Benton TD, Kee Ng WY, Leung D, Canetti A, Karnik N. Depression among youth living with
HIV/AIDS. Child Adolesc Psychiatr Clin N Am [Internet]. 2019;28(3):447–59. Available from:
http://dx.doi.org/10.1016/j.chc.2019.02.014
19. Tapullima-Mori,Calixto. Factores relacionados con la ansiedad y depresión en pacientes con
VIH de un hospital público. Rev. investig. Psicol. 2022, vol.25, n.2, pp.55-71. Epub 19-Dic-
2022. ISSN 1560-909X. Available from: http://dx.doi.org/10.15381/rinvp.v25i2.21424.
20. Jokelainen J, Timonen M, Keinänen-Kiukaanniemi S, Härkönen P, Jurvelin H, Suija K.
Validation of the Zung self-rating depression scale (SDS) in older adults. Scand J Prim Health
Care [Internet]. 2019 [Cited 2024 May 18];37(3):353–7. Available from:
http://dx.doi.org/10.1080/02813432.2019.1639923
21. Dunstan DA, Scott N. Clarification of the cut-off score for Zung’s self-rating depression scale.
BMC Psychiatry [Internet]. 2019 [Cited 2024 May 15];19(1). Available from:
http://dx.doi.org/10.1186/s12888-019-2161-0
22. Han H, Xia X, Zheng H, Zhong Z, Zhao C, Wang X, et al. Factors associated with the high
susceptibility to depression of women during the perimenopause. Brain Behav [Internet]. 2023
[Cited 2024 May 18];13(1). Available from: http://dx.doi.org/10.1002/brb3.2826
pág. 3592
23. Dunstan DA, Scott N. Norms for Zung’s Self-rating Anxiety Scale. BMC Psychiatry [Internet].
2020 [Cited 2024 May 16];20(1). Available from: http://dx.doi.org/10.1186/s12888-019-2427-
6
24. Del Águila Montoya LM, Pinedo Córdova MF, Soto Sánchez SS, Torres Dávila A, Tapullima-
Mori C. Escala de depresión de Zung: propiedades psicométricas en portadores del virus de la
inmunodefciencia humana. Revista de Salud UDH [Internet]. 16 de octubre de 2021 [Cited
2024 May 18];3(4):261-9. Available from:
http://revistas.udh.edu.pe/index.php/RPCS/article/view/358e
pág. 3593
APPENDIX
Graph 1
Graph 2
pág. 3594
Graph 3
Graph 4